nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

INTRODUCTION: The phase III MPACT trial in patients with metastatic pancreatic cancer (MPC) demonstrated superior efficacy of nab-paclitaxel (nab-P) plus gemcitabine (Gem) compared with Gem monotherapy, including the primary endpoint of overall survival (OS; median 8.7 vs. 6.6 months; hazard ratio [...

Descripción completa

Detalles Bibliográficos
Autores principales: Tehfe, Mustapha, Dowden, Scot, Kennecke, Hagen, El-Maraghi, Robert, Lesperance, Bernard, Couture, Felix, Letourneau, Richard, Liu, Helen, Romano, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882352/
https://www.ncbi.nlm.nih.gov/pubmed/27085323
http://dx.doi.org/10.1007/s12325-016-0327-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882352/
https://www.ncbi.nlm.nih.gov/pubmed/27085323
http://dx.doi.org/10.1007/s12325-016-0327-4

Ejemplares similares